Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well ...

A new partnership is combining a blood test, a cognitive app and national infrastructure to cut Britain’s years-long ...

MUST’s RETRO-EPIGERNA team won $1 million and a place in the $81 million finals, though key trial details remain undisclosed.

Oxford biotech secures $47 million to scale cell-based mRNA manufacturing, with an eye on therapies that require repeated ...

First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients.

Deep Longevity’s new US telehealth platform, Accrua, ties treatment plans to a blood-based aging score and re-tests every ...

At ARDD 2026, senior FDA officials sketch how a therapy targeting aging might one day reach approval, revealing that ...

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data ...

The Austin-based microbiome testing company raised a $33M Series B, and adults now outnumber babies in its testing volume.

Aged beagle data hint at lower biological age and preliminary muscle changes with SIRT6c treatment, although key readouts ...